ABSTRACT
@#Glucagon-like peptide-1(GLP-1), a polypeptide secreted by small intestinal L cells, has various effects including increasing insulin synthesis and secretion, suppressing appetite, and delaying gastric emptying. In addition to glucose control, GLP-1 has multiple functions in a variety of tissues and organs. A number of studies have shown that GLP-1 receptor agonists could treat a variety of chronic diseases, including diabetes, through antioxidant mechanisms. Based on oxidative stress, this paper summarizes the current progress in the synthesis & metabolism, pancreatic and extracantral effects, anti-oxidation effects of diabetes and its complications, aging, and neurological diseases of GLP-1, with an attempt to provide theoretical reference to researches on related oxidative stress mechanisms and development of new drug.
ABSTRACT
Objective: To study the effects of glucagon-like peptide-1(GLP-1) analogues on kidney function and kidney ultrastructure in type 2 diabetic rats. Methods: Twenty-eight SPF level male SD rats were randomly divided into control groups (normal control group and diabetic control group) and GLP-1 analogues Exenatide intervention groups(normal intervention group and diabetic intervention group). The effects of Exenatide intervention on glucose, lipid metabolism, kidney function and kidney ultrastructure were observed. Results: Fasting glucose, fasting insulin, insulin sensitivity index, insulin resistance index, lipid profile, 24-hours microalbuminuria, serum creatinine and blood urea nitrogen of Exenatide intervention group were much better than those of corresponding control groups. Through electron microscopy, glomerular mesangial cell in diabetic control group proliferated, basement membrane thickened, while glomerular mesangial cell in diabetic intervention group did not proliferate, basement membrane mildly thickened. Conclusion: GLP-1 analogues can improve kidney function of diabetic rats. Maybe it is connected with improving kidney ultrastructure.
ABSTRACT
Objective·To study the effects of glucagon-like peptide-1 (GLP-1) analogues on kidney function and kidney ultrastructure in type 2 diabetic rats.Methods·Twenty-eight SPF level male SD rats were randomly divided into control groups (normal control group and diabetic control group) and GLP-1 analogues Exenatide intervention groups (normal intervention group and diabetic intervention group).The effects of Exenatide intervention on glucose,lipid metabolism,kidney function and kidney ultrastructure were observed.Results·Fasting glucose,fasting insulin,insulin sensitivity index,insulin resistance index,lipid profile,24-hours microalbuminuria,serum creatinine and blood urea nitrogen of Exenatide intervention group were much better than those of corresponding control groups.Through electron microscopy,glomerular mesangial cell in diabetic control group proliferated,basement membrane thickened,while glomerular mesangial cell in diabetic intervention group did not proliferate,basement membrane mildly thickened.Conclusion·GLP-1 analogues can improve kidney function of diabetic rats.Maybe it is connected with improving kidney ultrastructure.
ABSTRACT
Objective To investigate the effects of liraglutide on the proliferation and differentiation of mouse pre-osteoblasts MC3T3-E1 exposed to higher glucose concentration. Methods MC3T3-E1 cells were cultured and divided into control group and liraglutide group. In liraglutide group, cells were treated with different liraglutide concentrations (10-9 mol/L, 10-8 mol/L, and 10-7 mol/L, respectively) for 48 hours. Cell proliferation was tested with CCK-8. The mRNA expressions of typeⅠcollagen (COL-Ⅰ), osteopontin (OPN), and alkaline phosphase ( ALP) were detected using semi-quantitative RT-PCR. Results ( 1 ) Compared to control group, the proliferation rate of different liraglutide concentration groups (10-9 mol/L, 10-8 mol/L, and 10-7 mol/L) increased significantly (all P<0. 05), the proliferation rate was the highest in 10-8mol/L liraglutide group. (2)The expression of COL-Ⅰ, OPN, and ALP mRNA in liraglutide groups were higher than those in control group (all P<0. 05). The optimal concentration of liraglutide was 10-8 mol/L. Conclusion Liraglutide within a certain concentration range may improve the proliferation and differentiation of mouse pre-osteoblasts MC3T3-E1.
ABSTRACT
The prevalence of diabetes is increasing worldwide. Glycemic control has been shown to prevent microvascular complications. Many oral hyperglycemic drugs and insulin are being used in the treatment of diabetes, but the effects of those treatments are suboptimal. The two incretin hormones GLP-1 and GIP are released from L- and K-cells, respectively, in response to nutrient intake. GLP-1 stimulates glucose-dependent insulin release. Recently, incretin hormone-based therapies, including GLP-1 agonists and DPP-4 inhibitors, have been used as new treatment options to control glucose levels in patients with type 2 diabetes mellitus. The purpose of this article is to review the efficacy and safety of GLP-1 agonists in the treatment of type 2 diabetes.
Subject(s)
Humans , Diabetes Mellitus, Type 2 , Glucagon-Like Peptide 1 , Glucose , Incretins , Insulin , PrevalenceABSTRACT
Objective To observe the therapeutic efficacy and safety of the glucagon-like peptide-1 ( GLP-1 )analogue combined with isulin for treating obese or overweight type 2 diabetes.Methods 40 cases with obese or overweight type 2 diabetic patients( body mass index(BMI) ≥24) who have previously used human insulin,and experienced poor glycemic control( ≥7.5％ ) were selected.They were randomly divided into two groups.A group treated by GLP-1 analogue liraglutide plus insulin,and B group by continuous adjustment of insulin.12 weeks later,fasting blood glucose(FBG),2-hour plasma glucose (2hPG),hemoglobin A 1 C (HbA1c),body weight were observed and the incidence of hypoglycemia,insulin dosage were recorded.Results Weight and insulin dosage of group A was significantly lower than those of group B after treatment 12 week( t =2.738,2.865,all P ＜ 0.01 ).Numbers of hypoglycemia events were 6 in group A(30％ ),and 9 in group B(45％ ),but there was no statistical significance between the two groups ( P ＞ 0.05).Conclusion The addition of liraglutide to insulin in patients with obese or overweight type 2 diabetes is associated with reductions in weight and insulin dosage,without increase risk of hypoglycemia.This treatment proved effective and safe.
ABSTRACT
Type 1 diabetes mellitus (TlDM) is an autoimmune disease characterized by the destruction of pancreatic β cells, which sequentially leading to the reduction of insulin secretion. Numerous susceptibilities, including genetic and environmental factors, may be involved in triggering the T1DM. The ideal therapy for T1DM should focus on both preventing the immune system from attacking β cells, and also the stimulation of β cell neogenesis. In vitro and in vivo studies both demonstrated that GLP-1 analogues were able to promote the synthesis and secretion of insulin, stimulate neogenesis of β cells, increase β cells replication, and reduce β cell apoptosis. Hence, GLP-1 analogues have been shown to be potential treatment for T1DM. This work reviewed recent publications regarding to GLP-1 application in TlDM and pancreatic islet transplantations and prospected the future research directions.